In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
HIGHLIGHTS
EVENTS
Kedrion Biopharma celebrates Primary Immunodeficiency Week
The company stands alongside PI patients associations around the globe
read moreEVENTS
Kedrion Biopharma celebrates World Hemophilia Day 2018
Support for patients with coagulation disorders worldwide is confirmed
read moreEVENTS
50-Year Anniversary of a Maternal Health Breakthrough
Kedrion Biopharma supports session on Anti-D achievements and challenges at FIGO Congress in Dubai
read more-
EVENTS - 13-07-2015
Revolutionary PID testing from Tuscany, Italy
Kedrion at Meyer Hospital’s side to promote early diagnosis of primary immunodeficiencies
read more -
CORPORATE - 29-06-2015
Humanitarian programme to reduce the gap in the access to clotting factors
Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London
read more -
EVENTS - 15-05-2015
Kedrion Continues Global Expansion with Dedication Ceremony at US Facility
Biopharma Company Celebrates with Local Guests and Dignitaries in Melville, New York
read more -
CORPORATE - 30-04-2015
Kedrion SpA’s Shareholders approve 2014 financial statement
A 466 million euros’ turnover with a 9,8% rise on 2013
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 